Addressing the Burden of Flare-Ups in Atopic Dermatitis | AMCP Nexus 2024

Atopic dermatitis (AD) is a chronic skin condition that significantly impacts patients' quality of life. Flare-ups, characterized by itchy, inflamed, and painful patches, can disrupt daily activities and emotional well-being. Recent research presented at the AMCP Nexus 2024 Annual Meeting highlighted the burden of flares on patients with AD and the importance of addressing the unmet needs in this patient population.

READ MORE: Dermatology Resource Center

Are you ready to elevate your pharmacy practice? Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips, straight to your inbox.

References

1. Gray C, Lucats L, Brookes E, et al. Unveiling the burden and impact of flare in patients with moderate to severe atopic dermatitis: Results from the Adelphi Real World Disease Specific Programme in the United States. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster L13.

2. Liu J, Bui B, Odo N, Bancroft T, Sturm D. Ruxolitinib cream utilization reduced other topical therapy, corticosteroid, and biologic use in patients with atopic dermatitis: US claims database analysis. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster L12.

3. Gray C, Joseph J, Cholasamudram S. Understanding the burden of flares in patients with moderate to severe atopic dermatitis: A targeted literature review. Presented at: AMCP Nexus 2024; October 14-17, 2024; Las Vegas, NV. Poster L16.